Differential expression and activation of Epidermal Growth Factor Receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC)

Experimental Lung Research

Volumn 39, Issue 9, 2013, Pages 387-398

  Gorgisen, Gokhan ^a   Ozes, Derya ^a   Pehlivanoglu, Suray ^a   Erdogan, Abdullah ^a   Dertsiz, Levent ^a   Ozbilim, Gulay ^a   Ozbudak, Irem Hicran ^a   Savas, Burhan ^a   Ozes, Osman Nidai ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

EGFR1; ERK; NSCLC; STAT3; TWIST1

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; PEPTIDES AND PROTEINS; PROTEIN KINASE B; PROTEIN TWIST1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; TWIST TRANSCRIPTION FACTOR;

EID: 84886800830     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2013.831960     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, CA Cancer J Clin. 2010;60:277-300.
2. Schiller JH, Harrington D, Belani C, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346: 92-98. (Pubitemid 34438899)
3. Sandler A, Gray R, Perry M, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEngl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
4. Patel JD, Pasche B, Argiris A: Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol. 2004;50:175-186. (Pubitemid 38746532)
5. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
6. Yatabe Y, Takahashi T, Mitsudomi T: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68(7):2106-2111. (Pubitemid 351521782)
7. Mitsudomi T, Kosaka T, Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11:190-198. (Pubitemid 44087117)
8. Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817-1824. (Pubitemid 350002184)
9. Sharma S, Bell W, Settleman J, Habler DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181.
10. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001; 2:127-137.
11. Putman EA, Yen N, Gallick GE, Steck PA, Fang K, Akpakip B, Gazdar AF, Roth JA: Autocrine growth stimulation by transforming growth factor-α in human non-small cell lung cancer. Surg Oncol. 1992;1:49-60.
12. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E: Differential expression of the epidermal growth factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379-2385. (Pubitemid 23156828)
13. Vivanco I, Sawyers CL:The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501. (Pubitemid 37328931)
14. Wada T, Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838-2849. (Pubitemid 38638846)
15. Kim EK, Choi E: Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta. 2010;1802:396-405.
16. Quesnelle KM, Boehm AL, Grandis JR: STAT-Mediated EGFR signaling in cancer. J Cell Biochem. 2007;102:311-319. (Pubitemid 47519405)
17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
18. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D: Growth factor receptor are associated with improved survival in gefitinibtreated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11(16):5878-5885.
19. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS. 2005;2(3):225-235.
20. Paez JG, Jënne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-1500. (Pubitemid 38720929)
21. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F: EGFR mutations in non-smallcell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23:857-865. (Pubitemid 46224186)
22. Nyati MK, Morgan MA, Feng FY, Lawrence TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6:876-885. (Pubitemid 44629899)
23. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS 2005;2(1):57-61.
24. Semenza GL: Targeting HIF1-a for cancer therapy. Nat Rev Cancer 2003;3:721-732.
25. Puisieux A, Wittmann SW, Ansieau S: A twist for survival and cancer progression. Br J Cancer 2006;94:13-17. (Pubitemid 43088534)
26. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DM, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jënne PA: Exon 19 deletion of epidermal growth factor receptor are associated with prolonged survival im non-smal cell lung cancerpatients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908-3914. (Pubitemid 44078074)
27. Paez JG, Jënne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500. (Pubitemid 38720929)
28. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Spanish Lung Cancer Group: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;362:958-967.
29. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinó L: Akt Phosphorylation and Gefitinib Efficacy in Patients ith Advanced Non-Small-Cell Lung Cancer. J Natl Cancer Inst. 2004;96(15):1133-1141. (Pubitemid 39207049)
30. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003;22:2812-2822. (Pubitemid 36609595)
31. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20):2499-2513. (Pubitemid 32531347)
32. Haura EB, Zheng Z, Song L, Cantor A, Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11(23):8288-8894.
33. Quesnelle KM, Boehm AL, Grandis JR: STAT-mediated EGFR signaling in cancer. J Cell Biochem. 2005;102:311-319. (Pubitemid 47519405)
34. Vesuna F, van Diest P, Chen JH, Raman V: Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367(2):235-241.
35. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7): 927-939 (Pubitemid 38798858)
36. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ: Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009;64(12):1082-1089.